Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Stemline Therapeutic (STML)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 367,290
  • Shares Outstanding, K 31,801
  • Annual Sales, $ 900 K
  • Annual Income, $ -67,830 K
  • 36-Month Beta 1.12
  • Price/Sales 348.11
  • Price/Cash Flow N/A
  • Price/Book 5.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.72
  • Number of Estimates 6
  • High Estimate -0.67
  • Low Estimate -0.85
  • Prior Year -0.93
  • Growth Rate Est. (year over year) +22.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.85 +17.26%
on 01/23/19
11.92 -3.10%
on 02/05/19
+0.87 (+8.15%)
since 01/18/19
3-Month
7.82 +47.70%
on 12/21/18
12.54 -7.89%
on 11/26/18
-0.18 (-1.53%)
since 11/21/18
52-Week
7.82 +47.70%
on 12/21/18
20.55 -43.80%
on 06/05/18
-5.00 (-30.21%)
since 02/21/18

Most Recent Stories

More News
Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Marriott International (NASDAQ:MAR),...

STML : 11.55 (-1.28%)
CVGW : 83.58 (+0.29%)
MAR : 127.37 (+0.32%)
KNSL : 61.66 (-0.61%)
FLDM : 10.73 (-0.46%)
GSBD : 21.05 (+0.72%)
Stemline Therapeutics Closes $92 Million Public Offering of Common Stock

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced...

JPM : 105.47 (-0.21%)
STML : 11.55 (-1.28%)
Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher

Stemline Therapeutics (STML) shares rose nearly 10% in the last trading session, amid huge volumes.

ACIU : 4.63 (+9.98%)
STML : 11.55 (-1.28%)
Stemline Therape Has Returned 32.6% Since SmarTrend Recommendation (STML)

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on October 15th, 2018 at $14.75. In approximately 3 months, Stemline Therape has returned 32.61% as of today's recent price of $9.94....

STML : 11.55 (-1.28%)
Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced...

JPM : 105.47 (-0.21%)
STML : 11.55 (-1.28%)
Stemline Therapeutics Announces Proposed Public Offering of Common Stock

Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced...

JPM : 105.47 (-0.21%)
STML : 11.55 (-1.28%)
Look for Shares of Stemline Therape to Potentially Rebound after Yesterday's 7.11% Sell Off

Stemline Therape (NASDAQ:STML) traded in a range yesterday that spanned from a low of $9.28 to a high of $9.28. Yesterday, the shares fell 7.1%, which took the trading range below the 3-day low of $9.68...

STML : 11.55 (-1.28%)
Shares of STML Down 29.6% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on October 15th, 2018 at $14.75. In approximately 3 months, Stemline Therape has returned 29.63% as of today's recent price of $10.38....

STML : 11.55 (-1.28%)
Stemline Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline's...

JPM : 105.47 (-0.21%)
STML : 11.55 (-1.28%)
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal

It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.

AGEN : 2.98 (-0.33%)
STML : 11.55 (-1.28%)
GILD : 65.55 (-2.13%)
ACOR : 13.38 (+2.14%)
SRRK : 16.96 (-5.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators are in flux.

See More Share

Trade STML with:

Business Summary

Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric...

See More

Key Turning Points

2nd Resistance Point 11.76
1st Resistance Point 11.66
Last Price 11.55
1st Support Level 11.45
2nd Support Level 11.34

See More

52-Week High 20.55
Fibonacci 61.8% 15.69
Fibonacci 50% 14.18
Fibonacci 38.2% 12.68
Last Price 11.55
52-Week Low 7.82

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar